Goetz Wehl

Dr. Goetz Wehl

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2005 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
WHWolfgang Högler
Wolfgang Högler
GWGoetz Wehl
Goetz Wehl
VSVictoria van Staa
Victoria van Staa
BMBernhard Meister
Bernhard Meister
AKAndreas Klein‐Franke
Andreas Klein‐Franke
GKGabriele Kropshofer
Gabriele Kropshofer

7 November 2018 in Current Pediatric Reviews
Verified
Journal Article
Closed access
PDF file
GWGoetz Wehl
Goetz Wehl
MRMarkus Rauchenzauner
Markus Rauchenzauner
Background and Objective: Melkersson Rosenthal syndrome (MRS) is a rare disorder of unknown etiology and comprises the triad: orofacial edema, recurrent facial paralysis and lingua plicata. In the current literature confusing heterogeneity exists, mixing together the historically grown terms cheilitis granulomatosa or granulomatous cheilitis, Melkersson Rosenthal syndrome and the umbrella term orofacial granulomatosis (OFG). Methods: We provide a systematic review comprising all three disease entities of orofacial granulomatosis using the computerized database “Pubmed Medline” entering the key words “orofacial granulomatosis” (141 references), “Melkersson-Rosenthal syndrome” (207 references), “granulomatous cheilitis” or “cheilitis granulomatosa” (102 references) back to 1956. Full text journals and case studies were included, and data synthesis was performed individually. Results: Etiology remains unclear for all three disease entities. Etiological relatedness to chronic inflammatory bowel disease is under discussion and effectiveness was found for different treatments, e.g. local triamcinolone injections, antibiotics, surgical interventions, TNF alpha blockers or exclusive enteral nutrition. No randomized controlled trial concerning the therapy of orofacial granulomatosis was found. As a consequence, therapeutic conclusions are drawn mainly from small case series, thus limiting the evidence of therapeutic interventions. Conclusions: OFG with the sub-entities MRS and cheilitis granulomatosa is an etiological obscure disease process with various possible therapeutic interventions potentially alleviating the disease course but to broaden treatment knowledge further study in randomized controlled trials are needed.

1 May 1999 in Medical and Pediatric Oncology
Verified
Journal Article
Closed access
PDF file
GWGoetz Wehl
Goetz Wehl
FAFranz Allerberger
Franz Allerberger
AHAndreas Heitger
Andreas Heitger
BMBernhard Meister
Bernhard Meister
KMKatrin Maurer
Katrin Maurer
FFFranz-Martin Fink
Franz-Martin Fink

11 May 2020 in Klinische Padiatrie
Verified
Journal Article
Closed access
PDF file
GWGoetz Wehl
Goetz Wehl
MLMonika Laible
Monika Laible
MRMarkus Rauchenzauner
Markus Rauchenzauner
In December 2019 a novel coronavirus was firstly encountered in Wuhan/China with a massive outbreak of fatal pneumonia leading to a pandemic declared by the World Health Organization in March 2020 (WHO Dashboard COVID-19. [WHO web site]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019), affecting mainly elderly adults with underlying co-morbidities. Clinical course in children below the age of 10 years is considered to be mild or even with subclinical signs (Sinha IP, Ha et al. The Lancet Respiratory medicine 2020;27;S2213–2600(20) 30152-1). We describe a 4 month old infant with co-infection of SARS CoV-2 and influenza A virus.

1 December 2004 in Oncology Research and Treatment
Verified
Journal Article
Closed access
GWGoetz Wehl
Goetz Wehl
Jochen Karl RösslerJochen Karl Rössler
Jochen Karl Rössler
JOJ. E. Otten
J. E. Otten
NBN. Boehm
N. Boehm
MUM. Uhl
M. Uhl
CNC. Niemeyer
C. Niemeyer
Patients with fibromatosis not amenable to surgery may suffer from high morbidity. Various chemotherapeutic regimens have been tried in these patients with limited success. Here, we report on the successful use of pegylated liposomal doxorubicin in the treatment of 4 patients with unresectable fibromatosis in unfavorable localizations. 3 children and 1 adult with progressive fibromatosis were treated with 3-weekly cycles of chemotherapy with liposomal doxorubicin (dose range 20-50 mg/m2 per day every 21 days). Tumors were located at the nasal cavity, fossa infratemporalis, oral cavity, abdomen, and fossa supraclavicularis and were unresectable. 3 of the 4 patients had been heavily pretreated with various chemotherapeutic agents. Objective tumor response was monitored by magnetic resonance imaging and possible cardiotoxicity by echocardiography at regular intervals. A tumor response was obtained in all 4 patients. All patients showed normal cardiac function after completion of chemotherapy as evaluated by left ventricular shortening fraction. Severe neutropenia was not observed. Pegylated liposomal doxorubicin is a therapeutic option in patients with progressive unresectable fibromatosis in unfavorable localizations.

4 August 2007 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
Jochen Karl RösslerJochen Karl Rössler
Jochen Karl Rössler
GWGoetz Wehl
Goetz Wehl
CNCharlotte Marie Niemeyer
Charlotte Marie Niemeyer